Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Clinical Cancer Research|2025Cited by 12
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinomaSusana Banerjee, George Coukos, Romuald Le Scodan et al.|Annals of Oncology|2021Cited by 4
Supplementary Figure S3 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Data from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0